Cannabis for Chronic Back Pain
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines how cannabis may help individuals with chronic back pain. Researchers aim to determine if cannabis can reduce the need for prescription opioids by acting as a pain reliever or by helping individuals lower their opioid doses. Participants will receive various combinations of THC (Tetrahydrocannabinol) and CBD, compounds found in cannabis, along with placebos. The trial may suit those who have experienced back pain for over three months and wish to reduce opioid use, provided they have not undergone major surgery recently or have other severe pain conditions. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potential new treatment options.
Will I have to stop taking my current medications?
The trial requires participants to stop using cannabis 14 days before the study and throughout the study. If you are currently using opioids, you must stop 14 days before the study and during the study if you are in the Analgesia Arm. Other medications like valproate, clobazam, clopidogrel, warfarin, barbiturates, and benzodiazepines are also not allowed.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that both THC and a combination of THC and CBD have been studied for safety in treating long-term pain. Studies suggest that side effects from THC are fairly common, occurring in about 26% of users, but these effects are usually mild and not serious. While some users may experience side effects, they are generally not severe.
For the THC/CBD combination, research indicates it is generally well-tolerated, especially compared to opioid painkillers. This combination has a good safety record, typically not causing serious side effects, with a low risk of addiction or misuse.
Overall, existing studies consider both treatments safe for most people. However, participants should discuss any concerns with healthcare providers before joining a trial.12345Why are researchers excited about this trial's treatments?
Researchers are excited about using THC and THC/CBD for chronic back pain because these compounds offer a potential alternative to traditional painkillers like opioids and NSAIDs, which can have significant side effects and addiction risks. THC and CBD, derived from cannabis, work by interacting with the body's endocannabinoid system, possibly providing pain relief with a different mechanism of action than standard treatments. This approach could lead to effective pain management with fewer side effects, making it a promising option for those who have not found relief with current medications.
What evidence suggests that this trial's treatments could be effective for chronic back pain?
Research has shown that treatments using THC and a mix of THC/CBD can help reduce chronic back pain. In this trial, participants will receive different treatment sequences, including THC alone, a THC/CBD combination, and a placebo. One study found that people using THC reported significantly less pain compared to those who received a placebo. Another study found that a combination of THC and CBD reduced pain by 42% to 66%. These findings suggest that cannabis-based treatments can effectively manage chronic pain. Additionally, using both THC and CBD together may better reduce pain and the desire for opioids than using THC alone. Overall, these treatments appear promising for individuals with chronic back pain.13678
Who Is on the Research Team?
Emily Lindley, PhD
Principal Investigator
University of Colorado, Denver
Are You a Good Fit for This Trial?
This trial is for adults with chronic, non-radiating spine pain lasting over 3 months. Participants must not have used cannabis or opioids recently and should be free from certain health conditions like cancer-related pain, neuropathic pain, recent major surgery, substance abuse disorders, significant mental health issues, cardiovascular disease, liver dysfunction or severe depression.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment - Analgesia Arm
Participants receive daily treatment with an oral cannabis solution in a crossover design for 6 weeks per treatment period
Treatment - Reduction Arm
Participants receive daily treatment with an oral cannabis solution or placebo for 13 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Placebo
- THC
- THC/CBD
Trial Overview
The study tests the safety and effectiveness of oral cannabis (THC/CBD combination or THC alone) compared to a placebo in reducing chronic spine pain and potentially decreasing opioid use. The goal is to see if cannabis can serve as an alternative to opioids for long-term pain management.
How Is the Trial Designed?
8
Treatment groups
Experimental Treatment
Placebo Group
Subjects in this parallel arm will be assigned to 13 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
Subjects in this crossover arm will be assigned to 6 weeks on THC/CBD oral solution, then 6 weeks on THC oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
Subjects in this crossover arm will be assigned to 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution, then 6 weeks on THC oral solution. Frequency of drug administration is 3-4 times a day.
Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on Placebo oral solution, then 6 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
Subjects in this crossover arm will be assigned to 6 weeks on Placebo oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on THC oral solution. Frequency of drug administration is 3-4 times a day.
Subjects in this crossover arm will be assigned to 6 weeks on Placebo oral solution, then 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
Subjects in this parallel arm will be assigned to 13 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
THC is already approved in United States, Canada, European Union for the following indications:
- Appetite loss and weight loss in HIV
- Nausea and vomiting from chemotherapy
- Appetite loss and weight loss in HIV/AIDS
- Nausea and vomiting from chemotherapy
- Appetite loss and weight loss in HIV/AIDS
- Nausea and vomiting from chemotherapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor
Institute of Cannabis Research
Collaborator
Colorado Department of Public Health and Environment
Collaborator
Citations
a phase 3 randomized placebo-controlled trial
Similarly, the rate of participants with a ≥50% pain reduction (32.2% versus 22.8%; P = 0.010) and a ≥2-point pain reduction (46.9% versus 35.6 ...
NCT06454669 | Dronabinol as an Adjunct for Reducing Pain
Collectively, these data suggest that cannabinoids may be more effective for chronic rather than acute pain conditions. ... Low Back PainChronic PainBack Injuries.
The Efficacy of Cannabis in Reducing Back Pain - PMC - NIH
At all time-points during the 8 hour session, there was a statically significant reduction in pain in both THC groups when compared to the placebo group.
Long-Term Cannabis Therapy for Chronic Low Back Pain
Short-term data suggest promise: a 2-week study of 249 CLBP patients found THC-dominant edibles significantly reduced pain, and observational ...
Efficacy of Dronabinol as an Adjuvant Treatment for ...
Results of the Phase I study showed that patients who received dronabinol experienced decreased pain intensity and increased satisfaction compared with placebo.
Long-term and serious harms of medical cannabis and ... - PMC
Very low certainty evidence suggests that adverse events are common (prevalence: 26.0%; 95% CI 13.2% to 41.2%) among users of medical cannabis for chronic pain.
Safety Considerations in Cannabinoid-Based Medicine - PMC
Cannabinoid-based medicines are associated with safety risks which should be assessed in the context of potential therapeutic benefits.
Dronabinol Useful for Chronic Pain: A Case Report
central neuropathic pain showed “that dronabinol is a safe long-term treatment option” with “no signs of drug abuse and only one possible.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.